# Atebimetinib

Source: https://onco.cc/drugs/atebimetinib/  
OnCo record `atebimetinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Atebimetinib is an experimental small-molecule drug from Immuneering in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at MEK1/2.

## Summary

Atebimetinib is a small-molecule drug developed by Immuneering. Its target is MEK1/2 (the sponsor names MEK). The sponsor states: Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07562152, plans to enrol 510 participants with primary completion expected 2028-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously.

## Sources

- ClinicalTrials.gov: trials of Atebimetinib: https://clinicaltrials.gov/search?intr=Atebimetinib
- Sponsor page: https://www.immuneering.com/pipeline

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [MEK1/2](https://onco.cc/targets/mek/)
- companies: [Immuneering](https://onco.cc/companies/immuneering/)
- trials: [Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07562152/)

---
JSON: https://onco.cc/api/v1/entities/atebimetinib.json